Evolva Holding Management

Management criteria checks 2/4

We currently do not have sufficient information about the CEO.

Key information

Chief executive officer

n/a

Total compensation

CEO salary percentage	n/a
CEO tenure	no data
CEO ownership	n/a
Management average tenure	4.8yrs
Board average tenure	4yrs

Recent management updates

Shareholders Will Probably Hold Off On Increasing Evolva Holding SA's (VTX:EVE) CEO Compensation For The Time Being

Apr 01

Recent updates

Shareholders Will Probably Hold Off On Increasing Evolva Holding SA's (VTX:EVE) CEO Compensation For The Time Being

Apr 01

Evolva Holding's (VTX:EVE) Shareholders Are Down 70% On Their Shares

Feb 13

We're Keeping An Eye On Evolva Holding's (VTX:EVE) Cash Burn Rate

Dec 21

CEO

Evolva Holding has no CEO, or we have no data on them.

Leadership Team

Name	Position	Tenure	Compensation	Ownership
Gerhard Lobmaier	Chief Operations Officer	3.3yrs	no data	no data
Thomas Schneckenburger	Head of Investor & Corporate Relations	no data	no data	no data
Philipp Frech	General Counsel & Secretary of the Board	2.3yrs	no data	no data
Anne De Vos	Head of Sales	no data	no data	no data
Astrid Schafer	Head of Innovation	6.3yrs	no data	no data
Luc Gruner	Executive Officer	6.8yrs	no data	no data

4.8yrs

Average Tenure

56.5yo

Average Age

Experienced Management: EVE's management team is considered experienced (4.8 years average tenure).

Board Members

Name	Position	Tenure	Compensation	Ownership
Beat In-Albon	Vice-Chairman of the Board	4yrs	CHF160.00k	0.21% CHF 14.5k
Karl-Heinz Altmann	Member of Scientific Advisory Board	no data	no data	no data
Jay Keasling	Member of Scientific Advisory Board	no data	no data	no data
Vincent Martin	Member of Scientific Advisory Board	no data	no data	no data
Jörg Bohlmann	Member of Scientific Advisory Board	8.7yrs	no data	no data
Birger Møller	Member of Scientific Advisory Board	no data	no data	no data
Karsten Kristiansen	Member of Scientific Advisory Board	no data	no data	no data
Stephan Schindler	Chairman of the Board	4yrs	CHF95.00k	0.15% CHF 10.0k

4.0yrs

Average Tenure

71yo

Average Age

Experienced Board: EVE's board of directors are considered experienced (4 years average tenure).

Evolva Holding Management

Management criteria checks 2/4

Key information

Recent management updates

Evolva Holding SA, Annual General Meeting, Apr 12, 2024

No independent directors

Evolva Holding SA Announces Management Appointments

No independent directors

Evolva Holding SA Announces Executive Changes

Shareholders Will Probably Hold Off On Increasing Evolva Holding SA's (VTX:EVE) CEO Compensation For The Time Being

Recent updates

Evolva Holding SA, Annual General Meeting, Apr 12, 2024

Evolva Holding SA ADR - Sponsored to Be Deleted from OTC Equity

Evolva Holding to Seek the Delisting of Its Shares from SIX Swiss Exchange

Danstar Ferment AG enters into an agreement to acquire Evolva AG form Evolva Holding SA (SWX:EVE) for CHF 30 million.

New major risk - Market cap size

We Think Evolva Holding (VTX:EVE) Has A Fair Chunk Of Debt

New major risk - Shareholder dilution

New major risk - Revenue and earnings growth

New major risk - Revenue and earnings growth

Evolva Receives Approval for Veri-Te Resveratrol in Thailand

Evolva Receives FDA Approval for Veri-teTM Resveratrol in Taiwan

Would Evolva Holding (VTX:EVE) Be Better Off With Less Debt?

Evolva Holding SA (VTX:EVE) Screens Well But There Might Be A Catch

Full year 2022 earnings released: CHF0.04 loss per share (vs CHF0.047 loss in FY 2021)

No independent directors

First half 2022 earnings released: CHF0.03 loss per share (vs CHF0.03 loss in 1H 2021)

Evolva Holding SA Provides Revenue Guidance for the Full Year 2022 and 2025

Evolva Holding SA to Report Fiscal Year 2022 Results on Mar 09, 2023

Evolva Holding SA announced that it has received CHF 6.3226 million in funding

Evolva Holding SA Announces Management Appointments

Price target decreased to CHF0.21

No independent directors

Is Evolva Holding (VTX:EVE) Using Debt In A Risky Way?

Forecast to breakeven in 2023

Forecast to breakeven in 2023

Price target decreased to CHF0.23

Full year 2021 earnings: EPS and revenues miss analyst expectations

Evolva Holding SA Announces Executive Changes

Forecast to breakeven in 2023

Evolva Holding SA announced that it expects to receive CHF 12 million in funding from Nice & Green SA

Is Evolva Holding (VTX:EVE) Weighed On By Its Debt Load?

First half 2021 earnings released: CHF0.03 loss per share (vs CHF0.02 loss in 1H 2020)

Evolva Holding SA announced that it expects to receive CHF 20 million in funding from Nice & Green SA

Shareholders Will Probably Hold Off On Increasing Evolva Holding SA's (VTX:EVE) CEO Compensation For The Time Being

Chief Financial Officer has left the company

Price target raised to CHF0.32

Earnings beat expectations, revenue disappoints

Evolva Announces Management Changes

Full year 2020 earnings released: CHF0.038 loss per share (vs CHF0.028 loss in FY 2019)

Evolva Holding's (VTX:EVE) Shareholders Are Down 70% On Their Shares

Evolva Launches L-Arabinose, a Natural Sugar Blocker and Reducing Sugar

New 90-day high: CHF0.24

We're Keeping An Eye On Evolva Holding's (VTX:EVE) Cash Burn Rate

Evolva Holding Sa Appoints Gerhard Lobmaier as Chief Operations Officer, Effective January 1, 2021

New 90-day low: CHF0.23

Processa Pharmaceuticals, Inc. Appoints Michael Floyd as Chief Operating Officer

Analysts update estimates

Evolva Holding SA to Report Fiscal Year 2020 Results on Feb 25, 2021

New 90-day high - CHF0.31

Evolva Holding SA announced that it expects to receive CHF 12 million in funding from Nice & Green SA

CEO

Leadership Team

Average Tenure

Average Age

Board Members

Average Tenure

Average Age